PRKCI Knockout HAP1 Cell Line

The choice depends on whether you are studying PRKCI (PKCι/aPKC)'s role as an atypical PKC isoform in cell polarity and oncogenic signaling or modeling its functions as a lung and ovarian cancer driver (3q26 amplification target). The Knockout line is the standard tool for asking whether PKCι is required for these processes — PKCι is an atypical PKC that does not require DAG or Ca²⁺ for activation, functioning in the Par complex (Par6-Par3-aPKC) for cell polarity establishment. Overexpression is useful for studying PKCι gain-of-function in cancer contexts. Important consideration: PKCι and PKCζ (PRKCZ) share substantial substrate scope as atypical PKCs — single PKCι knockout in HAP1 may show partial phenotypes if PKCζ compensates. PRKCI is a well-characterized oncogene amplified in lung squamous cell carcinoma and ovarian cancer (3q26 locus). Rescue with wild-type or kinase-dead (K274W) PKCι is the standard specificity control. The knockout is a critical specificity tool for aPKC inhibitors (auranofin, ICA-1S, ζ-Stat) in cancer drug development.

Primary applications: • aPKC substrate phosphorylation: phospho-Par3, phospho-LLGL1/2 Western blot to assess PKCι-dependent phosphorylation of polarity complex substrates. • Cell polarity assays: epithelial polarization in heterologous polarized cell models or 3D acinar morphogenesis given the Par complex's role in establishing polarity. • Cancer phenotype: proliferation, anchorage-independent growth, and migration analysis given PKCι's role as a 3q26-amplified oncogene in lung squamous cell carcinoma and ovarian cancer. • aPKC inhibitor specificity: critical genetic control for auranofin (FDA-approved gold compound being repurposed), ICA-1S, ζ-Stat, and other aPKC-targeting compounds. EDITGENE recommends this model for researchers investigating atypical PKC biology, cell polarity, lung cancer 3q26 amplification mechanisms, and aPKC-targeted drug development.

Yes. PKCι rescue experiments require attention to atypical PKC architecture: • Construct design: use a codon-modified PRKCI sequence with a small C-terminal tag (FLAG, HA). PKCι has N-terminal PB1 domain (Par6 binding), C1-like domain, pseudosubstrate, and C-terminal kinase domain — preserve all elements. • Kinase-dead rescue: the K274W mutation in the ATP-binding lysine abolishes catalytic activity and is the standard specificity control. • PB1 domain-mutant rescue: PB1 domain mutations disrupt Par6 binding and Par complex assembly, enabling separation of Par-dependent from Par-independent PKCι functions. • Functional readout: rescue should restore phospho-Par3, phospho-LLGL1/2, and downstream polarity/oncogenic phenotypes. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.